What Do Analysts Think About Gilead Sciences (GILD)?

Gilead Sciences, Inc. (NASDAQ:GILD) is one of the best affordable growth stocks to buy. In a report released on August 21, Evan Seigerman from BMO Capital reiterated a Buy rating on Gilead Sciences, Inc. (NASDAQ:GILD), setting a price target of $130.00.

Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector

Similarly, Bernstein raised the firm’s price target on Gilead Sciences, Inc. (NASDAQ:GILD) to $135 from $120 on August 20, keeping an Outperform rating on the shares.

The firm told investors in a research note that Gilead Sciences, Inc. (NASDAQ:GILD) reported EPS and Q2 revenue slightly above estimates, with the full year guidance raised as HIV performed better than expected.

Gilead Sciences, Inc. (NASDAQ:GILD) has a Strong Buy analyst consensus rating, with its median price target of $112.97 implying an upside of 14.19% from current levels.

Gilead Sciences, Inc. (NASDAQ:GILD) is a biotech company that advances medicines to prevent and treat serious diseases such as cancer, immunodeficiency virus (HIV), viral hepatitis, and COVID-19.

Its portfolio of drugs focuses on medical areas with unmet needs and includes AmBisome, Atripla, Biktarvy, Cayston, Complera, and others. Gilead Sciences, Inc. (NASDAQ:GILD) operates in over 35 countries.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.